JD Health International Inc.: history, ownership, mission, how it works & makes money

From its 2014 birth as JD.com's healthcare arm to a Hong Kong IPO that raised about HK$3.5 billion in December 2020 and the ticker 6618.HK, JD Health has rapidly evolved-launching JD Family Doctor in August 2020, a Rare Disease Care Program in 2021 and home nursing services in 2023-while reporting a striking 24.5% year-over-year revenue jump to RMB 35.3 billion in H1 2025 and a market cap of HK$191.29 billion as of 12 December 2025; this article unpacks how the JD.com subsidiary, now led by CEO Dong Cao and incentivizing staff with 299,090 Award Shares (≈0.01% of issued shares), combines AI (AI Jingyi serving over 50 million users as of August 2025), omnichannel retail, JD.com's logistics and partnerships with pharma and device makers to generate revenue-with 83.1% of H1 2025 revenue from product sales and 16.9% from services-while exploring advertising, technical services, online marketing and digital-health device sales to capture China's booming online healthcare market.

JD Health International Inc. (6618.HK): Intro

• Establishment: 2014 as JD.com's healthcare division, entering China's online healthcare market.
• IPO: Listed on the Hong Kong Stock Exchange in December 2020 (ticker: 6618.HK), raising approximately HK$3.5 billion from the initial public offering.
• Telemedicine rollout: In August 2020 launched "JD Family Doctor" for continuous, personalized family telehealth services.
• Rare disease initiatives: Introduced the "Rare Disease Care Program" in 2021 to provide supplies, professional care and financing solutions for rare-disease patients.
• Home nursing: Expanded into home nursing services in 2023 to enable professional in-home care for patients with complex or chronic conditions.
• Recent growth: Reported a 24.5% year-over-year revenue increase, reaching RMB 35.3 billion in H1 2025.

Ownership and Governance

• Parent linkage: Originated as a business unit of JD.com; significant shareholding and strategic alignment with JD.com and its affiliates.
• Public ownership: Traded on the HKEX (6618.HK) with institutional and retail investors participating post-IPO.
• Management focus: Leadership combines e-commerce logistics expertise with healthcare operators, emphasizing regulatory compliance, platform integration, and data security.

Mission and Strategic Priorities

• Mission: To make high-quality healthcare accessible and affordable across China through digital channels, integrated logistics, and clinical partnerships.
• Strategic pillars: expand telemedicine and family health services; scale e-pharmacy and medical supplies; deepen care for chronic and rare diseases; develop home-based care capabilities.
• Patient-centricity: Emphasis on continuity of care (e.g., JD Family Doctor), affordability (financing for high-cost treatments), and convenience (same-day/next-day delivery for medications).

How JD Health Works - Core Offerings & Customer Flow

• Online pharmacy: Prescription and OTC drug sales through JD Health's platform and app, combined with JD's logistics network for rapid delivery.
• Telemedicine & family care: Virtual consultations, e-prescriptions, chronic disease follow-up and JD Family Doctor subscription services.
• Clinical programs & specialty care: Programs such as Rare Disease Care provide bundled services-medical supplies, specialist consultations, and financing support.
• Home nursing & in-home services: Professional nursing and infusion services delivered at patients' homes for post-acute and complex-care needs.
• B2B and institutional services: Supply-chain solutions for hospitals and clinics, pharmaceutical distribution, and digital health tools for partners.

How JD Health Makes Money - Revenue Streams

• E-pharmacy sales: Transaction revenue from prescription and OTC drug sales, margin on products and value-added logistics.
• Telemedicine fees: Consultation fees, subscription revenues (e.g., family doctor packages), and pay-per-service virtual visits.
• Healthcare services: Revenue from home nursing, chronic disease management programs, and specialty disease programs (including rare disease services).
• B2B contracts: Distribution and supply-chain agreements with hospitals, clinics, and pharmaceutical manufacturers.
• Value-added offerings: Data services, health management SaaS, advertising and platform fees from third-party providers.

Key Historical and Financial Milestones

JD Health International Inc. (6618.HK): History

JD Health International Inc. (6618.HK) is the healthcare arm of the JD ecosystem, structured as a subsidiary of JD Jiankang Limited, which itself is a subsidiary of JD.com. The company combines e-commerce distribution, digital healthcare services and platform-enabled B2B offerings to serve consumers, healthcare providers and institutional customers.

• Ownership: Subsidiary of JD Jiankang Limited → JD.com (majority ultimate parent).
• Market capitalization (as of 12 Dec 2025): HK$191.29 billion.
• Employee incentives: Oct 2025 grant of 299,090 Award Shares under Post-IPO Share Award Scheme (~0.01% of total issued shares).
• Corporate governance & agreements: Sep-Nov 2025 saw strategic amendments, renewals and approvals of key commercial and shared-services agreements with JD.com, and an EGM in Nov 2025 approving multi-year annual caps for healthcare products and services.
• Leadership: Sep 2025 appointment of Mr. Dong Cao as CEO following prior executive resignations.

How it works & monetization:

• Retail pharmacy sales: direct-to-consumer drug and wellness product sales via JD's logistics network and platforms.
• Telemedicine & online consultations: fee-based virtual consultations and subscription health-management services.
• Platform & marketplace services: commission and listing fees from third-party healthcare merchants and brands.
• B2B solutions: supply-chain, procurement and digital health solutions for hospitals, clinics and institutional buyers.
• Cross-platform synergies: promotional and shared-services arrangements with JD.com drive traffic, fulfillment efficiencies and customer acquisition.

Key corporate links: Exploring JD Health International Inc. Investor Profile: Who's Buying and Why?

JD Health International Inc. (6618.HK): Ownership Structure

• Mission and Values: JD Health is committed to providing accessible and comprehensive online healthcare services, aiming to improve the quality of life for individuals across China.
• Innovation: The company emphasizes digital-health innovation, integrating AI, big data and telemedicine to improve service efficiency and user experience.
• Patient-centric services: JD Health delivers personalized offerings such as online medical consultations, health check-ups, prescription fulfillment and home care services.
• Social impact: JD Health supports underserved communities - for example, the Rare Disease Care Program launched in 2021 to assist patients with rare conditions.
• Ethics and transparency: The company stresses integrity, regulatory compliance and transparent interactions with patients, partners and investors.
• Continuous improvement: JD Health regularly updates its services and technology stack to meet evolving healthcare needs and user expectations.

• Online medical consultations and subscription services - paid consultations, membership and value-added services.
• Pharmacy sales and prescription fulfillment - retail OTC and prescription medicines, logistics-enabled delivery.
• Healthcare services and management - diagnostics, health check-ups, chronic-disease programs and home care.
• B2B solutions - enterprise health-management platforms, insurance partnerships and hospital integrations.
• Advertising and data services - targeted health marketing and analytics for partners (within regulatory limits).

JD Health International Inc. (6618.HK): Mission and Values

• Online medical consultations: real-time video and text consultations with licensed physicians across specialties, scheduling, follow-up and prescription issuance.
• AI-assisted triage and diagnostics: AI Jingyi (智能晶医) supports symptom triage, clinical decision support and clinician workflows; as of August 2025 it has served over 50,000,000 users.
• Health check-ups and chronic disease management: booking and management of physical exams, routine monitoring and longitudinal care plans.
• Home care & on-demand services: in-home sample collection, medication delivery, nursing and rehabilitation services coordinated via the platform.
• Pharmaceutical and OTC retail: omnichannel distribution combining direct sales, marketplace listings and on-demand delivery of drugs, supplements and medical devices.
• Interoperability and care records: user medical profiles, e-prescriptions and consultation histories accessible through the platform for continuity of care.

• AI and analytics: natural language processing, medical imaging assistance and predictive analytics to optimize clinician triage and downstream referrals.
• Omnichannel retail model: integrates direct inventory sales, third-party merchant marketplace and rapid (same/next-day) delivery leveraging JD's logistics network.
• Partnership network: formal collaborations with hospitals, clinics, licensed pharmacists and major pharmaceutical manufacturers to broaden product/service coverage.
• Logistics integration: tight coupling with JD.com's supply chain enables cold-chain and controlled-delivery capabilities for pharmaceuticals and consumables.

• Consultation fees and subscription services: paid online consultations, telemedicine subscriptions and value-added care plans (e.g., chronic disease management).
• Pharmaceutical and product sales: direct retail margin and commissions from third-party marketplace sales of prescription drugs, OTC medicines and medical devices.
• Platform services and SaaS for providers: fees for hospital/clinic connectivity, technology services, data analytics and AI tools.
• Logistics and fulfillment fees: revenue from fulfillment and expedited delivery services for healthcare products.
• Advertising and promotional services: sponsored listings, brand storefronts and targeted promotions for pharmaceutical partners.

• Collaborations with pharmaceutical manufacturers to list and supply prescription and OTC products through direct and marketplace channels.
• Affiliations with hospitals and licensed healthcare institutions to provide specialist consultations, referral pathways and joint care programs.
• Integration with JD.com's commerce and logistics ecosystem to provide rapid delivery, cold-chain support and last-mile healthcare fulfillment.

JD Health International Inc. (6618.HK): How It Works

• Primary customer channels: JD.com marketplace integration, standalone app, mini-programs, and partner hospital portals.
• Core offerings: prescription and OTC medicines, online medical consultations, health check-ups, home care, smart devices, and digital health solutions.
• Monetization partners: pharmaceutical manufacturers, hospitals, insurers, advertisers, and device makers.

• Patient acquisition - traffic from JD ecosystem, search, and referral; user registers and links medical records.
• Point-of-care engagement - users consult doctors online (paid or reimbursed), receive e-prescriptions, and purchase medications on-platform.
• Fulfillment and logistics - integrated cold-chain and last-mile delivery fulfill pharmacy orders; bundled home care dispatched as needed.
• Recurring monetization - subscription services, follow-up consultations, chronic disease management programs, and device-data subscriptions.
• Business monetization - advertisers buy access to targeted user segments; healthcare brands pay for technical integration and promotional placement.

• High-margin pharmacy sales and scale logistics drive the bulk of revenue (83.1% in H1 2025).
• Service revenue (16.9% in H1 2025) grows via telemedicine, health checks, and home care, improving ARPU.
• Advertising, technical services, and marketing offerings monetize platform reach and user data.
• Device sales and digital-health SaaS expand addressable market into remote monitoring and hospital IT.

JD Health International Inc. (6618.HK): How It Makes Money

• Market capitalization: HK$191.29 billion (as of December 12, 2025).
• Revenue growth: 24.5% year-over-year to RMB 35.3 billion in H1 2025.
• AI adoption: AI Jingyi served over 50 million users as of August 2025, improving triage, customer service, and prescription workflows.
• Service expansion: added home nursing and rare disease care programs to capture higher-margin, specialized care segments.
• Strategic partnerships: collaborations with major pharmaceutical companies and medical device brands to broaden inventory, co-develop programs, and enhance referral networks.
• New business models: exploring AI integration across operations and on-demand retail for faster fulfillment and higher frequency transactions.

• Monetization mechanics:
  • Retail margins and logistics on pharmacy sales.
  • Consultation fees and subscription packages for chronic disease management.
  • Enterprise services: data analytics, supply-chain solutions and advertising/marketplace fees from pharma partners.
  • Specialty programs (rare disease, home nursing): premium pricing and long-term care contracts.
• Future outlook drivers:
  • Deeper AI integration to lower marginal service costs and increase throughput.
  • Expansion of high-margin specialized care to improve revenue mix.
  • Cross-selling between JD Group ecosystem and JD Health for customer acquisition and logistics leverage.